Bone-marker levels in patients with prostate cancer: Potential correlations with outcomes

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 3, 2010, Pages 127-134

  Saad, Fred ^a   Lipton, Allan ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Antiresorptive; Bisphosphonate; Bone metastases; Bone turnover markers; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CLODRONIC ACID; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; DENOSUMAB; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PEPTIDE; TUMOR MARKER; ZOLEDRONIC ACID;

ARTICLE; BONE TUMOR; DISEASE COURSE; HUMAN; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RISK ASSESSMENT; TREATMENT OUTCOME;

ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CLODRONIC ACID; COLLAGEN TYPE I; DIPHOSPHONATES; DISEASE PROGRESSION; HUMANS; IMIDAZOLES; MALE; PEPTIDES; PROGNOSIS; PROSTATIC NEOPLASMS; RANK LIGAND; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78449284191     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32833ac6d6     Document Type: Article

References (53)

1. Garcia M, Jemal A, Ward EM, et al. Global cancer facts & figures, 2007. Atlanta, Georgia, USA: American Cancer Society; 2007
2. Lipton A. Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention. J Support Oncol 2004; 2:205-213; discussion 213-214, 216-217, 219-220
3. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468
4. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003; 88:5059-5075. A comprehensive review of bone-turnover markers and how they are generated during bone remodeling
5. Roato I, D'Amelio P, Gorassini E, et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 2008; 3:e3627
6. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88:2919-2926
7. Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol 2003; 170:S55-S57; discussion S7-S8
8. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005:CD003474
9. Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95:1300-1311
10. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebocontrolled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007; 99:765-776
11. Dearnaley DP, MasonMD, Parmar MK, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009; 10:872-876. A key publication detailing the long-term survival benefit with clodronate in men with metastatic hormone-sensitive prostate cancer, providing proof of principle for the potential use of bone-protective agents as adjuvant therapy
12. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744
13. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613-2621
14. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882 (Pubitemid 38807610)
15. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005; 96:964-969
16. Saad F. New research findings on zoledronic acid: Survival, pain, and antitumour effects. Cancer Treat Rev 2008; 34:183-192
17. European Medicines Agency. European public assessment report: Zometa; 2010 http://www.ema.europa.eu/humandocs/Humans/EPAR/zometa/zometa. htm. [Accessed 5 March 2010]
18. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003; 9:2394-2399
19. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59-69. A study showing correlations between elevated bone-marker levels and increased risks of skeletal complications in patients with bone metastases who did not receive bone-protective therapy
20. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935. The first study showing correlations between bone-marker levels before initiation of bisphosphonate treatment and the risks of on-treatment skeletal morbidity in patients with bone metastases
21. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113:193-201. The first demonstration of bone-marker normalization during bisphosphonate therapy correlating with improved clinical outcomes in patients with malignant bone disease
22. Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial. J Urol 2009; 182:509-515; discussion 515-516
23. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564-1571. A study demonstrating the bone-marker-lowering effect of second-line denosumab treatment in patients with malignant bone disease who had elevated marker levels despite bisphosphonate therapy
24. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy. Eur Urol 2007; 51:1175-1184
25. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostatespecific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918-2925
26. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006; 12:3361-3367. A study showing the correlation between elevated bone-marker levels and poor survival in the bone-metastatic prostate cancer setting
27. Lein M, Wirth M, Miller K, et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007; 52:1381-1387
28. Lein M, Miller K, Wirth M, et al. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 2009; 69:624-632. A second study in an unrelated patient population confirming the correlations between bone-marker levels and risk of skeletal morbidity first reported by Coleman et al. [20*]
29. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 2003; 61:993-998
30. Saad F. N-telopeptide of type I collagen (NTX) response to zoledronic acid in patients with bone metastases from prostate cancer [abstract #411]. In: Socié té Internationale d'Urologie (SIU) World Uro-Oncology Update Meeting; 19-22 November 2008; Santiago, Chile
31. Brown JE, McCloskey EV, Dewar JA, et al. The use of bone markers in a 6- week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 2007; 81:341-351
32. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25:4431-4437
33. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14:6690-6696
34. Leeming DJ, Koizumi M, Byrjalsen I, et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15:32-38
35. Koizumi M, Yonese J, Fukui I, et al. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001; 87:348-351
36. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20:850-856
37. Koopmans N, de Jong IJ, Breeuwsma AJ, et al. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: A longitudinal approach. J Urol 2007; 178:849-853; discussion 853; quiz 1129
38. Lyubimova NV, Pashkov MV, Tyulyandin SA, et al. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 2004; 138:77-79
39. Salminen E, Ala-Houhala M, Korpela J, et al. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol 2005; 44:742-747
40. Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 2004; 111:783-791
41. Jung K, Lein M, von Hosslin K, et al. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 2001; 47:2061-2063
42. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Crit Rev Oncol Hematol 2006; 60:201-215
43. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154-164
44. Chang SS. Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: Implications in the management of prostate cancer. Urology 2003; 62:29-35
45. Kastelan D, Giljevic Z, Kraljevic I, et al. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males. Med Hypotheses 2006; 67:1052-1053
46. Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res 2004; 10:2705-2708
47. Basaria S, Lieb J 2nd, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56:779-786
48. Brufsky A, Harker G, Beck T, et al. Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer receiving letrozole as adjuvant therapy: A 5-year study (Z-FAST) [poster, abstract #2067]. Cancer Res 2009; 69.
49. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonistinduced bone loss in men with prostate cancer. J Clin Oncol 2007; 25:1038-1042
50. Ishizaka K, Machida T, Kobayashi S, et al. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007; 14:1071-1075
51. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007; 5:271-277
52. Magno C, Anastasi G, Morabito N, et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate. Eur Urol 2005; 47:575-580; discussion 580-581
53. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755. The first report of the activity of denosumab for preserving BMD and preventing fractures in men with hormone-sensitive prostate cancer (without bone metastases).